Eastman et al., 1998 - Google Patents
Aerosolization of cationic lipid: pDNA complexes—in vitro optimization of nebulizer parameters for human clinical studiesEastman et al., 1998
View PDF- Document ID
- 879901210744876425
- Author
- Eastman S
- Tousignant J
- Lukason M
- Chu Q
- Cheng S
- Scheule R
- Publication year
- Publication venue
- Human gene therapy
External Links
Snippet
Previously, we have described the optimization of the aerosol delivery of a nonviral gene therapy vector to the lungs of rodents (Eastman et al., 1997b). Although aerosolizing cationic lipid: pDNA complexes into a whole-body exposure chamber resulted in high levels of …
- 239000006199 nebulizer 0 title abstract description 105
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/30—Macromolecular compounds
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eastman et al. | A concentrated and stable aerosol formulation of cationic lipid: DNA complexes giving high-level gene expression in mouse lung | |
| AU2001244391B9 (en) | Devices and formulations | |
| US20150328232A1 (en) | Prostacylin compositions and methods for using the same | |
| Eastman et al. | Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid: DNA complexes | |
| Niven et al. | Nebulization of liposomes. I. Effects of lipid composition | |
| EP0611567B1 (en) | Ultrafine powder for inhalation and production thereof | |
| JP3708553B2 (en) | Powder-type pharmacological composition having improved dispersibility | |
| CA1292182C (en) | Intrapulmonary delivery of polypeptide growth factors and cytokines | |
| Lu et al. | Liposomal dry powders as aerosols for pulmonary delivery of proteins | |
| US5049389A (en) | Novel liposome composition for the treatment of interstitial lung diseases | |
| Eastman et al. | Aerosolization of cationic lipid: pDNA complexes—in vitro optimization of nebulizer parameters for human clinical studies | |
| KR100799089B1 (en) | Deposition Enhancement Compositions of Aerosolized Drugs | |
| WO2015138423A9 (en) | Prostacylin compositions and methods for using the same | |
| JPH05507090A (en) | Direct spray-dried drug/lipid powder compositions | |
| AU2001244391A1 (en) | Devices and formulations | |
| JP2002538855A (en) | Compressed air inhaler for pulmonary application of liposome powder aerosol and powder aerosol suitable therefor | |
| WO1996027393A1 (en) | A dry powder formulation for gene therapy | |
| Vartiainen et al. | Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice | |
| KR100666837B1 (en) | Stabilization of Lipid: DNA Formulations During Spraying | |
| Bains et al. | In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler | |
| Eljamal et al. | In situ and in vivo methods for pulmonary delivery | |
| US6375980B1 (en) | Stabilization of lipid:DNA formulations during nebulization | |
| Khezri¹ et al. | Advances in Pulmonary Nanopharmacology | |
| Bhattarai et al. | Karthik Nagapudi, Ajit S. Narang, and Ram I Mahato | |
| TAYLOR¹ et al. | The School of Pharmacy, University of London, 29-39 Brunswick Square |